Vastness
Bluelight Crew
Primary question is in the thread title - what is going on here? I have read it various places but I do not really understand fully how an agonist can have this affect.
I know there are different types of benzodiazepine receptors (subunits? someone correct my terminology if needed, please!) and the various ~benzodiazepines (for purposes of discussion I'm including thienotriazolobenzodiazepines in this class) have different binding affinities for a given set of receptor subunits. So I'm presuming that etizolam does not upregulate every receptor type that it binds to - it just happens to have this paradoxical effect on a very specific group of receptors, either as a direct consequence of the binding activity or as a result of some kind of "downstream" feedback mechanism which is harder to quantify.
Anyway, I would just love if someone could shed some light on this for me! Both in hard scientific terms of the relative binding affinities of etizolam to each receptor subunit as they compare to, say, a more classical benzo, diazepam or alprazolam perhaps - as well as, if possible, or known, which receptors are upregulated and why this happens.
Given that this weird shit happens with etizolam, is it possible that somewhere down the line in a more enlightened future of ultra-high-specificity AI-driven drug production we could have complementary benzodiazepine derivatives - for example - or perhaps even for other classes of drug - with almost perfectly opposing actions in terms of their upregulation/downregulation of the subunits of the receptor groups they exert their action at, such that we could have long term therapies alternating 2 such yin/yang variations of a similar chemical to counter the brain's tendency to try to develop tolerance to any exogenous agents?
Any answers or speculation welcome! Thanks in advance.
I know there are different types of benzodiazepine receptors (subunits? someone correct my terminology if needed, please!) and the various ~benzodiazepines (for purposes of discussion I'm including thienotriazolobenzodiazepines in this class) have different binding affinities for a given set of receptor subunits. So I'm presuming that etizolam does not upregulate every receptor type that it binds to - it just happens to have this paradoxical effect on a very specific group of receptors, either as a direct consequence of the binding activity or as a result of some kind of "downstream" feedback mechanism which is harder to quantify.
Anyway, I would just love if someone could shed some light on this for me! Both in hard scientific terms of the relative binding affinities of etizolam to each receptor subunit as they compare to, say, a more classical benzo, diazepam or alprazolam perhaps - as well as, if possible, or known, which receptors are upregulated and why this happens.
Given that this weird shit happens with etizolam, is it possible that somewhere down the line in a more enlightened future of ultra-high-specificity AI-driven drug production we could have complementary benzodiazepine derivatives - for example - or perhaps even for other classes of drug - with almost perfectly opposing actions in terms of their upregulation/downregulation of the subunits of the receptor groups they exert their action at, such that we could have long term therapies alternating 2 such yin/yang variations of a similar chemical to counter the brain's tendency to try to develop tolerance to any exogenous agents?
Any answers or speculation welcome! Thanks in advance.